Abalos Therapeutics Completes Series A Extension Bringing Total Raised To Eur 43 Million
Round Type
Series A
DüsseldorfBiotechnologyHealth CareScience And EngineeringDescription
Abalos Therapeutics announced today an extension to its Series A funding round bringing the total raised in this round to EUR 43 million (USD 50 million). The extension was led by Seventure Partners with support from Coparion, Ventura BioMed Investors and Hx Bio Ventures as well as contributions from existing investors from the initial Series A round including Boehringer Ingelheim Venture Fund (BIVF), Gründerfonds Ruhr, NRW.BANK and High-Tech Gründerfonds (HTGF). The financing underscores the potential of Abalos’ differentiated immuno-virotherapy approach to generate a maximal immune response specifically targeted against a patient’s cancer and its metastases. The proceeds will enable the company to advance its first product candidate into a Phase 1/2 trial in multiple solid tumors including the expansion cohorts to demonstrate early signs of clinical efficacy as well as fund further pipeline expansion.
Quick answer
Abalos raised an undisclosed amount in a Series A round, dated October 14, 2021. Abalos is based in Düsseldorf, North Rhine-Westphalia, Germany.
- How much did Abalos raise?
- Abalos raised an undisclosed amount in a Series A round on October 14, 2021.
- What does Abalos do?
- Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer cells.
- Where is Abalos based and how big is it?
- Abalos is based in Düsseldorf, North Rhine-Westphalia, Germany.
- Who are the decision-makers at Abalos?
- Fundz holds 1 contact at Abalos. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Biotechnology around the same time
Companies in the same sectors as Abalos that raised within 45 days of this round, from Fundz verified event records.
- Lysogene raised $4.6M (Seed) on November 26, 2021.
- SEELOS THERAPEUTICS, INC. raised $20M (Convertible Note) on November 24, 2021.
- Wheeler Bio raised $14M on November 23, 2021.
- Stilla Technologies raised an undisclosed amount on November 23, 2021.
- Deka Biosciences, Inc. raised $16M on November 23, 2021.
- RedHill Biopharma Ltd raised $5M on November 22, 2021.
Who to call at Abalos, and when
A new round usually means Abalos is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Abalos raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Abalos, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Abalos. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Abalos raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAbalos raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.